Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232667 | 0.98 | MAPT (0.44) | MAPTKMT2ANPSR1MEN1HPGD | |
| SCHEMBL11811988 | 0.79 | DUSP3 (0.39) | MAPTKMT2ANPSR1MEN1HPGD | |
| SCHEMBL1426317 | 0.72 | LMNA (0.49) | MAPTKMT2ANPSR1MEN1HPGD | |
| SCHEMBL6232883 | 0.72 | LMNA (0.60) | MAPTKMT2ANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2161809 | 0.71 | OPRL1 (0.51) | KMT2AALDH1A1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL14045645 | 0.71 | CYP2C9 (0.53) | MAPTKMT2ANPSR1KDM4EALDH1A1 | |
| SCHEMBL5268831 | 0.70 | LMNA (0.54) | MAPTKMT2ANPSR1MEN1HPGD | |
| SCHEMBL20808156 | 0.70 | ALDH1A1 (0.49) | MAPTKMT2ANPSR1MEN1HPGD | |
| SCHEMBL11808256 | 0.70 | JAK2 (0.42) | MAPTKMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20079633 | 0.69 | ALDH1A1 (0.47) | MAPTKMT2ANPSR1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | claimed |
| EP-0194226-A1 | A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-09-10 | — | — | EP | claimed |
| JP-63166870-A | — | — | None | — | — | JP | disclosed |
| EP-3010889-B1 | ARYLSULFIDE AND ARYLSULFOXIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2018-10-03 | — | — | EP | disclosed |
| US-9981928-B2 | Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20160130240-A1 | ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | US | disclosed |
| EP-3010889-A1 | ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202505-A1 | ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2014-12-24 | — | — | WO | disclosed |
| EP-1243261-B1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1018339-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of intractable vasculitis. | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-10-10 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| JP-S63166870-A | IMIDAZOLIDINETRIONE DERIVATIVE AND REMEDY CONTAINING SAID COMPOUND AS ACTIVE INGREDIENT FOR ALLERGIC DISEASE | NIPPON ZOKI PHARMACEUT CO LTD | 1988-07-11 | — | — | JP | disclosed |
| US-4683240-A | HYPOGLYCEMIC, HYPOUPIDEMIC | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0194226-A1 | A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130240-A1 | ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | ARSA, SQOR, AHR | MAPT 2874/4885KMT2A 2528/4885NPSR1 747/4885 |
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | ALB, TTR, SERPINA6 | MAPT 4117/4885KMT2A 4295/4885NPSR1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.